Videos

Our Science Explained

We believe that science and data should be discussed, not just read.

Our videos are meant to provide additional information and context to enable everyone to meaningfully interpret the ongoing stream of information.

VBI-1901: SNO Phase 2a Data & Clinical Update

November 19, 2020

Jeff Baxter and David E. Anderson, Ph.D., discuss updated Phase 2a (Part B) data of VBI-1901 in recurrent GBM patients, as presented at SNO 2020.

Watch NowArrow

Sci-B-Vac® Late-Breaker Oral Presentation at EASL 2020

August 31, 2020

Adam Finn, M.D., Ph.D., discusses Data from the Sci-B-Vac® Phase 3 program at EASL.

Watch NowArrow

Preclinical Coronavirus Program Data Webcast

August 26, 2020

VBI discusses preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.

Watch NowArrow

VBI-1901: AACR Data and Clinical Update

June 22, 2020
Watch NowArrow

VBI-1901: AACR 2020 Webcast

June 22, 2020

David E. Anderson, Ph.D., discusses updated Part B data from the VBI’s ongoing Phase 1/2a study of VBI-1901.

Watch NowArrow

First- and Second-Generation Hepatitis B Vaccines

October 27, 2016
Watch NowArrow

VBI-1901 Therapeutic Cancer Vaccine Design

October 26, 2016
Watch NowArrow

Preclinical Studies in Glioblastoma (“GBM”)

October 25, 2016

In preclinical studies, VBI demonstrated that its vaccine candidate stimulated immune responses critical to efficacious anti-tumor immunity.

Watch NowArrow

Next Steps in the Development of Sci-B-Vac™

October 25, 2016

Sci-B-Vac™ is a licensed third-generation hepatitis B vaccine that has demonstrated safety and efficacy in over 300,000 patients. Sci-B-Vac™ is currently approved for use in Israel and in 14 other countries.

Watch NowArrow

About Medulloblastoma (“MB”)

October 25, 2016

Medulloblastoma is the most common malignant primary brain tumor in children.

Watch NowArrow

About Glioblastoma (“GBM”)

October 25, 2016

Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than sixteen months.

Watch NowArrow

LPV™ Thermostability Platform

October 25, 2016
Watch NowArrow

About Hepatitis B

October 15, 2016

Hepatitis B is a disease of the liver caused by the hepatitis B virus (“HBV”) characterized by inflammation, injury, and even cell death.

Watch NowArrow

Cytomegalovirus (“CMV”) Vaccine Candidate

August 15, 2014
Watch NowArrow

Enveloped Virus-Like Particle (“eVLP”) Platform Technology

August 5, 2014
Watch NowArrow


Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up Now for our newsletterArrow
Go top